Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis D in real clinical practice: a prospective cohort study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study

NCT06078722

Metabolic-associated Fatty Liver Disease (MAFLD)

UNKNOWN

Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes

NCT06691412

Hepatitis B Virus Steatosis

NOT_YET_RECRUITING PHASE3

6-week Safety and PD Study in Adults With NAFLD

NCT03256526

Non-alcoholic Fatty Liver Disease

COMPLETED PHASE2

Statin Impact on Hepatic Decompensation

NCT05563389

Quality of Life

COMPLETED PHASE2/PHASE3

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NCT03912532

NASH - Nonalcoholic Steatohepatitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Viral Hepatitis B With Delta-Agent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Cohort

Patients taking Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate

No interventions assigned to this group

Control cohort

Patients who do not take Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of both sexes aged 18 to 75 years who are citizens of the Republic of Kazakhstan;
* An established diagnosis of CGD (chronic viral hepatitis B with the delta agent);
* Patients who have contraindications to taking peg-INF-alpha2a and/or have failed treatment with peg-INF-alpha2a;
* Compensated liver disease ≤ CPT A (6 points);
* Patients without severe concomitant diseases;
* Patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others);
* Patients who voluntarily signed the informed consent form.

Exclusion Criteria

* Patients taking COC for more than 4 weeks before inclusion in the study;
* Patients with contraindications to the COC;
* Decompensated liver disease severity class \> CPT A6;
* Patients taking peg-IFN-alpha 2a;
* Alcohol abuse according to the AUDIT-c questionnaire;
* Pregnancy and lactation;
* Patients with coinfection with HIV, HCV;
* GFR ≤ 15 ml/min/1.73 m2;
* Exclude patients with significant biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 norms;
* Patients with other causes of liver damage;
* Drug addict people;
* Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than 5 times or more;
* Patient takes part in an interventional clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No